News / Health

    Pricey Hepatitis C Drug Draws Criticism

    Activists display placards during a rally at the AIDS Conference 2014 at the Melbourne Convention and Exhibition Centre (MCEC) in Melbourne, on July 22, 2014. Activists display placards during a rally at the AIDS Conference 2014 at the Melbourne Convention and Exhibition Centre (MCEC) in Melbourne, on July 22, 2014.
    x
    Activists display placards during a rally at the AIDS Conference 2014 at the Melbourne Convention and Exhibition Centre (MCEC) in Melbourne, on July 22, 2014.
    Activists display placards during a rally at the AIDS Conference 2014 at the Melbourne Convention and Exhibition Centre (MCEC) in Melbourne, on July 22, 2014.
    Anita Powell

    To hear scientists talk about it, it’s nothing short of a wonder drug.

    The drug is sofosbuvir, called Solvadi by its manufacturer, and its effectiveness in treating hepatitis C is so pronounced that the U.S. regulators designated it “breakthrough therapy” when they approved it for U.S. markets last year.

    The catch is that it doesn’t come cheap: a single pill costs $1,000, meaning the 12-week daily dose prescribed for most patients will cost $84,000. That has brought howls of protests from activists accusing California-based Gilead Sciences of charging extortionate prices.

    The dispute highlights the continuing conundrum afflicting medical research and spiraling health care costs, not only in the United States and elsewhere. What’s an appropriate price to charge for life-changing, or life-saving, drug therapies and who determines it?

    Pharmaceutical companies argue they spend billions of dollars to research, discover and test such breakthrough drugs, so the production costs account for just a fraction of the company’s overall investment.

    Activists-- some of whom traveled to the International AIDS conference in Melbourne, Australia, to protest Gilead’s decisions-- say drug companies gouge customers and patients with arbitrary pricing that varies widely from place to place.

    “We want Gilead to explain, number one, on what they’re basing their price, whether it’s $84,000 in Europe and the United States, or even $2,000 in another country,” said Karyn Kaplan, who directs international Hepatitis and HIV policy and advocacy for the New York-based organization, the Treatment Action Group. “We want to understand what is their price based on and why won’t they give a price that will be affordable to all who need it.”

    Gregg Alton, executive vice president for corporate and medical affairs for Gilead Sciences, said the drug is priced differently around the world. In Egypt, for example, which has a high rate of hepatitis C, the drug will cost just $300 per month.

    Alton also noted that the company will give generic licensing to several factories, which will push down the price in the future.

    “It is a fantastic drug. It’s really changing the landscape of Hepatitis C and the ability to treat hepatitis C, from a largely untreatable disease to one we can cure with a more than 90 percent rate,” he told VOA.

    A study by researchers at the University of Liverpool concluded that the Solvadi pill can be made for a few U.S. cents, and that even at $1 a pill, Gilead will make a healthy profit. 

    Alton said in considering the drug’s price, one should take into account that a patient who is cured of hepatitis C is free not only from the disease, but also the financial burden of future treatments.

    “So actually on a cost basis, if you just look at pure cost, it is actually less expensive than treating HIV, because HIV being chronic, if you actually put the cost of actually treating for life, it turns out to be more,” Alton said. “And, again, the other thing is that we actually hope the cost comes down, that’s the purpose of the generic licensing.”

    As many as 150 million people around the world have the chronic version of this liver disease that is spread, like HIV, through blood or sexual contact, according to the World Health Organization. For that reason, many HIV patients are at higher risk for contracting hepatitis C. Symptoms tend to surface late in the disease’s path, and can lead to liver cancer.

    As a whole, the hepatitis family of viruses kills about 1 million people per year, according to the WHO.

    For now, Gilead is raking in profits. Earlier this week, the company announced second-quarter sales of Sovaldi at a whopping $3.5 billion. That puts this little yellow pill on track to be one of the pharmaceutical industry’s biggest all-time hits, with sales expected to reach those of cholesterol-lowering drug Lipitor.

    “We are not at all against Gilead making money. They are a corporation, they are a for-profit entity. So we all recognize and agree that originator companies make investments, and that they should be appropriately rewarded,” Kaplan said. “However, what that appropriate reward is and the lack of transparency in how pharmaceutical originators, pharmaceutical companies come up with that price, is not in touch with reality.”

    You May Like

    Chechen Suspected in Istanbul Attack, but Questions Remain

    Turkish sources say North Caucasus militants involved in bombing at Ataturk airport, but name of at least one alleged attacker raises doubts

    With Johnson Out, Can a New ‘Margaret Thatcher’ Save Britain?

    Contest to replace David Cameron as Britain’s prime minister started in earnest Thursday with top candidates outlining strategy to deal with Brexit fallout

    US Finds Progress Slow Against Human Trafficking in Africa

    Africa continues to be a major source and destination for human trafficking of all kinds -- from forced labor to sexual slavery, says State Department report

    This forum has been closed.
    Comment Sorting
    Comments page of 2
        Next 
    by: John
    July 29, 2014 11:22 AM
    Sam. Your approach certainly sounds like the most sensible one. You'd have to make sure you weren't ripped off by counterfeits though. But I can't think of a general solution to the overall problem. Stricter testing procedures raise the cost of drugs, and activists whine about the cost to non-white, non-Western users, so Westerners, particularly US citizens, subsidize $300 payments in Egypt by paying $84 000 themselves. One may note that Africans refuse to recognize Western patents, so the 'charitable' pharma firms are backing MSF's testing of the new sleeping sickness drug. The cost is naturally added to our bills.

    by: Julie Dinkins-Borkowski
    July 28, 2014 2:04 AM
    I have been trying to get activist to notice the Cf drug that is hardly a cure is going to cost patients and their families $300,000 a year. And these drug companies are causing people to lose their insurance and lose their livelihood because no one wants to hire someone with such high priced health needs. Drug company execs are making billions off the backs of poor sick people, and no one cares.

    by: CaliforniaDreaming from: Ventura
    July 27, 2014 8:21 PM
    The uproar seems to be mostly from the PMB's who are concerned only with drug costs and payments. The health insurers are the ones who benefit since this drug is a cure for a deadly disease. They save the potential payments of liver cancer treatments, transplants, and all the late stage problems that dwarf the cost of Sovaldi. If one looks at the OVERALL picture, the drug cost is minor in comparison, though $84,000 is not a minor cost; but what is the cost of a life?

    by: Jonathan from: NYC
    July 27, 2014 8:10 PM
    This must be the gazillioneth time that an article has been written about the price of Solvaldi! Shut up already! Insurance Co's like United Health Care are paying their Execs $10-30 Million plus and Exxon books $5-10 billion dollars per quarter and nobody says anything. Isn't Provenge just as expensive and doesn't offer a cure? All the political healthcare activist should just shut up and by the stock! I did @ $63 last October! Market forces will solve any long term problems. This is America people!

    by: edwin cameron from: australia
    July 27, 2014 7:12 PM
    meanwhile they rake in billions of $$$ and the people that can't afford the drug suffer,has anyone thought about how contagious hep c is??commonsense dictates supply = eradication,as usual Greedy Big Pharma can't get it's snout out of the trough and the virus keeps destroying family's and peoples lives,as for that comment about Gay and drug addicts deserving the cost,well i won't dignify an answer,he is clearly a [insult redacted]!!

    by: Trust Gendron
    July 27, 2014 2:38 PM
    @ John Rudy
    Not all Hep C is contracted through immoral acts. I have Hep C and got mine from a Tattoo before the Tattoo industry became
    regulated by State and Fed laws.
    Here are a few more ways Baby Boomers contracted Hep C :

    *Blood transfusion or blood therapy or solid organ transplant performed before 1992, when a highly sensitive test to screen blood for hepatitis C was developed.
    *Kidney dialysis.
    *Blood products used to treat clotting problems made before 1987.
    *Health care workers who have been exposed to HCV-contaminated blood through a needle stick or splashes to the eye.
    *Infants born to infected mothers.
    SO IN THE FUTURE, PLEASE RESEARCH YOUR FACTS BEFORE YOU COME OFF AS IGNORANT...

    by: Colin Newton from: Pennsylvania
    July 27, 2014 9:59 AM
    Three ways to limit the price of drugs:
    1) A very expensive part of drug development is clinical trials, especially phase 3. Clinical trials could be run limiting payments to doctors and hospitals and could be designed by the FDA and the drug applicants.
    2) Limit payment of executives (CEOs, CFOs, presidents etc.) to an ethically acceptable amount (why does anyone need more than $10 million a year?).
    3) Restructure corporate and individual tax for health care companies.

    by: abbey Lynn from: wisconsin
    July 27, 2014 5:48 AM
    Really? I'm a 35 year old suburban housewife with two kids and I have it. I've never made any poor decisions that lead to my Hep C. I was born with a congenital heart defect and had open heart surgery when I was two. I contracted it when I was two via a blood transfusion. Get your head out of your rear please.

    by: kDavis26 from: Madison, WI, USA
    July 27, 2014 2:44 AM
    I can see both sides of this debate. My only thought is that it shouldn't be only about Solvaldi. There are arthritis medicines that cost $60,000 per year, year after year, possibly with the patient living 25 more years and never being cured. I have a relative with severe Alzheimer's who suffered a heart attack and is in a home that costs $12,000 per month, and doesn't have enough cognition to know she's even there.

    I'm OK with putting a cap on the cost/benefit ratio for medicine - we won't pay more than X for each additional healthy month some treatment is expected to create, or something along those lines, but let's not make it specific to one medicine. If Solvaldi is too expensive, ok, but then everything with a worse cost/benefit ratio is also too expensive.

    by: John Rudy from: Seattle , Washington USA
    July 26, 2014 11:56 PM
    Hepatitis is primarily contracted through IMMORAL sex acts and / or ILLEGAL IV drug addiction . I say let these people pay for their own consequences , not others !!!
    Comments page of 2
        Next 

    Featured Videos

    Your JavaScript is turned off or you have an old version of Adobe's Flash Player. Get the latest Flash player.
    Clinton Leads Trump, But Many Voters Don't Like Eitheri
    X
    Jim Malone
    June 29, 2016 6:16 PM
    In the U.S. presidential race, most recent polls show Democrat Hillary Clinton with a steady lead over Republican Donald Trump as both presumptive party nominees prepare for their party conventions next month. Trump’s disapproval ratings have risen in some recent surveys, but Clinton also suffers from high negative ratings, suggesting both candidates have a lot of work to do to improve their images before the November election. VOA National correspondent Jim Malone has more from Washington.
    Video

    Video Clinton Leads Trump, But Many Voters Don't Like Either

    In the U.S. presidential race, most recent polls show Democrat Hillary Clinton with a steady lead over Republican Donald Trump as both presumptive party nominees prepare for their party conventions next month. Trump’s disapproval ratings have risen in some recent surveys, but Clinton also suffers from high negative ratings, suggesting both candidates have a lot of work to do to improve their images before the November election. VOA National correspondent Jim Malone has more from Washington.
    Video

    Video Slow Rebuilding Amid Boko Haram Destruction in Nigeria’s Northeast

    Military operations have chased Boko Haram out of towns and cities in Nigeria’s northeast since early last year. But it is only recently that people have begun returning to their homes in Adamawa state, near the border with Cameroon, to try to rebuild their lives. For VOA, Chris Stein traveled to the area and has this report.
    Video

    Video New US Ambassador to Somalia Faces Heavy Challenges

    The new U.S. envoy to Somalia, who was sworn into office Monday, will be the first American ambassador to that nation in 25 years. He will take up his post as Somalia faces a number of crucial issues, including insecurity, an upcoming election, and the potential closure of the Dadaab refugee camp in Kenya. VOA’s Jill Craig asked Somalis living in Kenya’s capital city Nairobi how they feel about the U.S. finally installing a new ambassador.
    Video

    Video At National Zoo, Captivating Animal Sculptures Illustrate Tragedy of Ocean Pollution

    The National Zoo in Washington, D.C., is home to about 1,800 animals, representing 300 species. But throughout the summer, visitors can also see other kinds of creatures there. They are larger-than-life animal sculptures that speak volumes about a global issue — the massive plastic pollution in our oceans. VOA's June Soh takes us to the zoo's special exhibit, called Washed Ashore: Art to Save the Sea.
    Video

    Video Baghdad Bikers Defy War with a Roar

    Baghdad is a city of contradictions. War is a constant. Explosions and kidnappings are part of daily life. But the Iraqi capital remains a thriving city, even if a little beat up. VOA's Sharon Behn reports on how some in Baghdad are defying the stereotype of a nation at war by pursuing a lifestyle known for its iconic symbols of rebellion: motorbikes, leather jackets and roaring engines.
    Video

    Video Melting Pot of Immigrants Working to Restore US Capitol Dome

    The American Iron Works company is one of the firms working to renovate the iconic U.S. Capitol Dome. The company employs immigrants of many different cultural and national backgrounds. VOA’s Arman Tarjimanyan has more.
    Video

    Video Testing Bamboo as Building Material

    For thousands of years various species of bamboo - one of the world's most versatile plants - have been used for diverse purposes ranging from food and medicine to textiles and construction. But its use on a large scale is hampered because it's not manufactured to specific standards but grown in the ground. A University of Pittsburgh professor is on track to changing that. VOA’s George Putic reports.
    Video

    Video Orphanage in Iraqi City Houses Kids Who Lost their Parents to Attacks by IS

    An orphanage in Iraqi Kurdistan has become home to scores of Yazidi children who lost their parents after Islamic State militants took over Sinjar in Iraq’s Nineveh Province in 2014. Iraqi Kurdish forces backed by the U.S. airstrikes have since recaptured Sinjar but the need for the care provided by the orphanage continues. VOA’s Kawa Omar filed this report narrated by Rob Raffaele.
    Video

    Video Re-Opening Old Wounds in a Bullet-Riddled Cultural Landmark

    A cultural landmark before Lebanon’s civil war transformed it into a nest of snipers, Beirut’s ‘Yellow House’ is once again set to play a crucial role in the city.  Built in a neo-Ottoman style in the 1920s, in September it is set to be re-opened as a ‘memory museum’ - its bullet-riddled walls and bunkered positions overlooking the city’s notorious ‘Green Line’ maintained for posterity. John Owens reports from Beirut.
    Video

    Video Brexit Resounds in US Presidential Contest

    Britain’s decision to leave the European Union is resounding in America’s presidential race. As VOA’s Michael Bowman reports, Republican presumptive nominee Donald Trump sees Britain’s move as an affirmation of his campaign’s core messages, while Democrat Hillary Clinton sees the episode as further evidence that Trump is unfit to be president.
    Video

    Video NASA Juno Spacecraft, Nearing Jupiter, to Shed Light on Gas Giant

    After a five-year journey, the spacecraft Juno is nearing its destination, the giant planet Jupiter, where it will enter orbit and start sending data back July 4th. As Mike O'Sullivan reports from Pasadena, California, the craft will pierce the veil of Jupiter's dense cloud cover to reveal its mysteries.
    Video

    Video Orlando Shooting Changes Debate on Gun Control

    It’s been nearly two weeks since the largest mass shooting ever in the United States. Despite public calls for tighter gun control laws, Congress is at an impasse. Democratic lawmakers resorted to a 1960s civil rights tactic to portray their frustration. VOA’s Carolyn Presutti explains how the Orlando, Florida shooting is changing the debate.

    Special Report

    Adrift The Invisible African Diaspora